Latest news with #XPeng
&w=3840&q=100)
Business Standard
4 days ago
- Automotive
- Business Standard
Leapfrogging the world: China's rise in EVs, green energy and biotech
In the global race for technological supremacy, the spotlight has long fallen on Silicon Valley or Europe's innovation hubs. But behind the scenes, China is not merely catching up, it is rapidly emerging as a global frontrunner, spearheading transformative progress across electric vehicles (EVs), renewables, and biotechnology. Fuelled by state-backed strategies, relentless innovation, and manufacturing muscle, China's ascent is not just changing industries, it is redefining the world's technological future. EV boom: How China became the world's largest electric vehicle market China now controls the world's largest EV market, selling over 11 million units annually and accounting for more than 50 per cent of global EV sales. Companies like BYD, NIO, XPeng, and Li Auto have aggressively expanded beyond Chinese borders, with BYD overtaking Tesla in total global EV sales in 2025. China's dominance in EV exports is equally notable. In 2024, it shipped out 1.2 million EVs—surpassing Japan to become the world's top automobile exporter. Once mocked for low-cost knock-offs, Chinese EVs now compete on both price and advanced tech in Europe, Southeast Asia, and North America. According to Bloomberg, China's EV sales reached 11 million units in 2024, capturing nearly two-thirds of the global market, compared to 17 per cent in Europe and just 7 per cent in the US. In Q1 2025 alone, Chinese EV sales rose 55 per cent to 1.64 million units, outpacing Europe's 28 per cent (574,000) and the US' 18 per cent (301,000). What explains China's electric vehicle dominance? At the heart of China's EV power lies control over battery technology. With 70 per cent of global EV production and two domestic giants, CATL and BYD, supplying 55 per cent of the world's batteries, China enjoys unmatched battery pricing and efficiency. Fierce local competition has driven breakthrough innovations, bringing battery costs below $100/kWh for lithium iron phosphate (LFP) batteries, reaching price parity with combustion engines, a milestone still out of reach in the West. China's vertically integrated supply chain accounts for 75 per cent of lithium-ion battery production, and dominates cobalt/lithium refining and cathode/anode materials. In contrast, European and US supply chains remain fragmented and face 20 per cent higher production costs. Technologies like battery-swap stations and vehicle-to-grid (V2G) integration are giving Chinese EVs a technological and cost advantage. How state strategy fuels China's EV ecosystem Under the 'Made in China 2025' plan, China has built a powerful EV ecosystem through massive subsidies, sustained infrastructure investment, and long-term supply chain planning. It already boasts 20 times more public EV chargers than the US, and four times as many as Europe. China's renewable energy dominance breaks all global records In the renewables sector, China's lead is even more formidable. As of mid-2025, its solar capacity stood at 887 GW, with wind at 521 GW. The country invested $625 billion in clean energy in 2024 alone, according to Reuters. By comparison, the US has just 239 GW of solar, and the EU a combined 540 GW of wind and solar. In 2024, China added 445 GW of new renewables, 60 per cent of global additions. It builds three out of every four solar and wind installations worldwide and is on track to exceed its 2030 emissions targets ahead of schedule. China also manufactures over 80 per cent of the world's solar panels and dominates every stage of the solar and battery supply chain. Economies of scale, vertical integration, and heavy subsidies let Chinese producers outprice global competitors. Chinese biotech: From copycats to cutting-edge drug developers China's biotechnology sector is undergoing a dramatic transformation. Once known for generics, Chinese drugmakers are now innovating at scale. Bloomberg's analysis of Norstella data shows that China had over 1,250 novel drug candidates in 2024, closing in on the US (1,440) and far ahead of the EU. Back in 2015, that number was just 160. Chinese biopharma companies, once burdened with quality concerns, are increasingly earning approvals and partnerships with global regulators and pharma majors. By 2024, Chinese firms accounted for 31 per cent of all innovative drug pipelines globally, second only to the US. Policy reforms and returning scientists reshape Chinese biotech China's shift began in 2015 with sweeping reforms to its drug regulatory framework, accelerating approvals, enforcing global data standards, and encouraging repatriation of overseas-trained researchers. Coupled with the Made in China 2025 strategy, these efforts triggered a biotech investment boom. By 2024, China had overtaken the EU in expedited approvals from the FDA and EMA. Faster drug approvals and global impact Take Legend Biotech's cell therapy for blood cancer—marketed by Johnson & Johnson. It not only outpaced a US-made rival but also secured expedited review in multiple markets. Although Chinese firms still focus on refining existing therapies more than inventing new ones, their innovation pipeline is expanding. Of the world's top 50 companies with the most innovative drug candidates between 2020 and 2024, 20 are Chinese—up from just five in the prior five-year period. Jiangsu Hengrui, once a generic drugmaker, now leads globally in the number of new drug candidates added. Global pharma giants race to license Chinese innovations Western pharma majors are rushing to partner with Chinese firms: > Akeso Inc. licensed its cancer drug to Summit Therapeutics for $500 million upfront, seen as China biotech's 'DeepSeek moment' > Pfizer signed a record $1.2 billion upfront deal in May 2025 with 3SBio Inc. for a cancer therapy > Merck, AstraZeneca, and Roche have all snapped up Chinese drug assets According to DealForma, such high-value licensing deals are growing in both number and value. China's clinical trial edge: speed and scale A key advantage for Chinese biotech is speed. Thanks to vast patient pools and centralised hospitals, trial recruitment in China happens twice as fast as in the US. Lower costs allow companies to run multiple clinical trials simultaneously, boosting success odds. Since 2021, China has led the world in new clinical trial starts, ahead of the US, per GlobalData. However, challenges remain. The FDA still requires multinational data, limiting the use of China-only trials for US approvals. US reacts to China's biotech rise with new policy anxieties As US-China tensions rise, China's biotech progress has drawn concern in Washington. A congressional report warned that the US may cede leadership in another strategic domain. Policymakers are calling for tighter export restrictions and faster domestic drug approval processes. The China model: What makes its rise hard to replicate Across EVs, renewables, and biotechnology, China's strategy follows a clear pattern: centralised industrial planning, global supply chain dominance, technology at scale, and relentless execution speed. For the West, the question is no longer if China can lead in innovation, but how soon, and how far.
Yahoo
09-07-2025
- Automotive
- Yahoo
An EV Price War Hasn't Stopped XPeng Stock. Should You Buy XPEV Now?
China's electric vehicle market has been roiled by a fierce price war in 2025, with giants like BYD (BYDDY) slashing prices so deeply that insiders warn it's 'not sustainable.' Late last month, regulators even stepped in. Premier Li Qiang decried the 'involutionary' competition and urged brands to end their 'loss‑leading' tactics. Yet amid the chaos, XPeng (XPEV) has quietly stood out, delivering over 30,000 vehicles for eight straight months. While peers such as Nio (NIO), Zeekr (ZK) and even Tesla (TSLA) struggle with thinning margins and softening demand, XPeng's steady deliveries suggest robust consumer appetite and a resilient strategy. Now, with Beijing cracking down on 'disorderly' discounting, the playing field may finally stabilize, potentially giving XPEV room to shine. Nvidia Scores Another Sovereign AI Win. How Should You Play NVDA Stock Here? Dear Amazon Stock Fans, Mark Your Calendars for July 8 CoreWeave Seals the Deal to Buy Core Scientific. Should You Buy CRWV Stock Here? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. So, as the EV battlefield reshapes itself, XPeng looks like a rare winner worth a closer look at right now. Headquartered in Guangzhou, China, it is a prominent player in the smart electric vehicle (EV) market. The company designs, develops, manufactures, and markets a range of smart EVs. Its product lineup includes the P7 and P7i sports sedans, the G9 and G6 SUVs, the X9 seven-seater multi-purpose vehicle (MPV), and the MONA M03 all-electric hatchback coupe. XPeng operates globally, with a significant presence in Europe and Asia, focusing on the mid to high-end segments in China's vehicle market. Valued at $17 billion by market cap, XPeng shares have jumped over 140% in the past 52 weeks and extended their rally into 2025, up about 52% year‑to‑date, thanks to its rising sales. Valuation wise, XPEV looks challenging, with a price-book ratio of 4.1x, significantly higher than the sector median of 2.6x, indicating the stock might be overvalued compared to its peers. Similarly, its price-sales ratio of 1.49x is considerably above the sector median of 0.9x, further suggesting a premium valuation. Remarkably, XPeng has thrived over competitors in sales. In Q2 2025, it delivered 103,181 vehicles (a record quarter) and 197,189 in the first half of 2025, already surpassing its entire 2024 volume. June deliveries alone hit 34,611 units, up 224% year-over-year. XPeng notched eight straight months above 30,000 deliveries. By contrast, peers Nio and Li Auto (LI) saw much more modest growth (Nio's June was 24,900 units, +17% year-over-year, while Li's June sales actually fell). XPeng's growth is driven by an expanding lineup and heavy investment in AI driving tech. The company claims its in-house 'Turing' self-driving chip is 3x more powerful than Nvidia's (NVDA). It is also rapidly expanding overseas. XPeng is now selling in over 40 countries. In short, strong execution has kept XPeng's momentum intact, even as rivals scrambled to cut prices. For example, XPeng sold out 10,000 preorders of its new G7 SUV in 46 minutes. CEO He Xiaopeng has openly challenged Tesla's Model Y with the new G7, highlighting its superior interior space and advanced tech features. With every model launch and technology demo, XPeng reinforces its 'smart car' narrative, helping to justify the stock's recent strength. XPeng delivered a strong Q1 2025, exceeding analysts' expectations, reporting total revenues of $2.18 billion, up 141.5% year‑over‑year. The net loss narrowed to $97 million, or $0.10 per ADS, versus a $203 million loss a year earlier. Gross margin expanded to 15.6%, up 2.7 points, while vehicle margin rose to 10.5%, driven by improved pricing power and scale. At quarter‑end, XPeng held $6.2 billion in cash, equivalents and short‑term investments, providing ample liquidity for R&D and charging‑network expansion. Management projects Q2 2025 revenue growth of 237.5% to 257.5% and deliveries of 102,000–108,000 units, targeting full‑year profitability by Q4 2025. XPeng's record deliveries, widening margins and robust cash cushion support a cautiously optimistic outlook for sustainable growth throughout the year. Turning to Wall Street, analysts seem fairly upbeat on XPEV stock, tagging it as a 'Moderate Buy.' Of the 16 experts Barchart follows, nine call it a 'Strong Buy,' two echo the 'Moderate Buy' view, four recommend a 'Hold,' and one flags a 'Strong Sell.' With a 12‑month average target of $23.70, there's still over 35% upside potential from current levels. On the date of publication, Nauman Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-07-2025
- Automotive
- Yahoo
XPENG Announces Vehicle Delivery Results for June and First Half 2025
34,611 vehicles delivered in June, up 224% YoY Achieved a new record quarterly deliveries of 103,181 units in Q2 2025 First-half 2025 deliveries hit 197,189 units, surpassing total deliveries in 2024 30,000+ monthly deliveries sustained for eight consecutive months GUANGZHOU, China, July 01, 2025 (GLOBE NEWSWIRE) -- XPeng Inc. ('XPENG' or the 'Company,' NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle ('Smart EV') company, today announced its vehicle delivery results for June and the first half of 2025. In June 2025, XPENG delivered 34,611 Smart EVs, representing a year-over-year increase of 224% and marking the eighth consecutive month that deliveries exceeded 30,000 units. In the second quarter of 2025, XPENG delivered 103,181 Smart EVs, setting a new quarterly record. This brings XPENG's total deliveries for the first half of 2025 to 197,189 Smart EVs, surpassing its full-year 2024 total deliveries. XNGP achieved a monthly active user penetration rate of 85% in urban driving in June 2025. Most recently, XPENG was invited to present its advancements in foundational models for autonomous driving at the 2025 Conference on Computer Vision and Pattern Recognition (CVPR), the sole Chinese automotive company to receive this industry distinction. On June 19, 2025, XPENG launched its flagship model, XPENG X9, in Indonesia. The Company also announced that the right-hand drive X9 model for the Indonesian market will be manufactured locally in July, marking a crucial milestone in its global expansion roadmap. As of June 2025, XPENG has entered more than 40 countries and regions worldwide. About XPENG XPENG is a leading Chinese Smart EV company that designs, develops, manufactures, and markets Smart EVs that appeal to the large and growing base of technology-savvy middle-class consumers. Its mission is to drive Smart EV transformation with technology, shaping the mobility experience of the future. In order to optimize its customers' mobility experience, XPENG develops in-house its full-stack advanced driver-assistance system technology and in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrical/electronic architecture. XPENG is headquartered in Guangzhou, China, with main offices in Beijing, Shanghai, Shenzhen, Silicon Valley and San Diego. The Company's Smart EVs are mainly manufactured at its plants in Zhaoqing and Guangzhou, Guangdong province. For more information, please visit Safe Harbor Statement This announcement contains forward-looking statements. These statements are made under the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'will,' 'expects,' 'anticipates,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates' and similar statements. Statements that are not historical facts, including statements about XPENG's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: XPENG's goal and strategies; XPENG's expansion plans; XPENG's future business development, financial condition and results of operations; the trends in, and size of, China's EV market; XPENG's expectations regarding demand for, and market acceptance of, its products and services; XPENG's expectations regarding its relationships with customers, suppliers, third-party service providers, strategic partners and other stakeholders; general economic and business conditions; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in XPENG's filings with the United States Securities and Exchange Commission. All information provided in this announcement is as of the date of this announcement, and XPENG does not undertake any obligation to update any forward-looking statement, except as required under applicable law. Contacts: For Investor Enquiries: IR Department XPeng Inc. Email: ir@ Jenny Cai Piacente Financial Communications Tel: +1 212 481 2050 / +86 10 6508 0677 Email: xpeng@ For Media Enquiries: PR Department XPeng Inc. Email: pr@ Source: XPeng Inc.
Yahoo
02-07-2025
- Automotive
- Yahoo
XPeng (NYSE:XPEV) Achieves Record Deliveries in 2025 Amid Global Expansion
XPeng recently announced significant achievements, including the delivery of 34,611 Smart EVs in June 2025—a 224% year-over-year increase—and the launch of its flagship model, XPENG X9, in Indonesia, marking its expansion into over 40 countries. Despite these milestones, the company's stock faced a 5% decline over the last month. This is particularly interesting as broader markets, exemplified by the Nasdaq and S&P 500, saw gains. Factors such as positive market trends might have partly countered XPeng's decline, but the company's robust delivery performance and international expansion seem misaligned with its stock movement. Buy, Hold or Sell XPeng? View our complete analysis and fair value estimate and you decide. Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. The recent milestones achieved by XPeng, including a significant year-over-year increase in Smart EV deliveries and the expansion into Indonesia, could positively influence the company's long-term growth narrative. However, despite these developments, the company's stock recorded a 5% decline in the past month, contrasting with broader market gains on the Nasdaq and S&P 500. This divergence may suggest that while operational achievements are evident, investors remain cautious due to potential short-term margin pressures from ongoing R&D and expansion investments. Over the past year, XPeng's total return, including share price and dividends, was an impressive 139.32%. This remarkable performance highlights its strong recovery, although the company's stock price remains sensitive to market sentiment and economic conditions. The EV sector generally outperformed the market, with XPeng outperforming both the US Auto industry, which saw a 41.6% return, and the broader US Market, which returned 13.9% over the past year. Despite this outperformance, XPeng's current trading value above its consensus price target of US$19.91 suggests that market expectations might be optimistic. Subsequent revenue and earnings forecasts could see adjustments influenced by XPeng's international ventures and AI commitments. Analysts have assumed annual revenue growth of 24%, with earnings projected to improve as new technologies gain traction. However, these forecasts depend on XPeng managing costs and delivering on growth prospects amidst heightened competition and market expansion challenges. The current share price of US$22.64 supports an optimistic outlook, yet it exceeds the analyst price target by 13.7%, indicating disagreements among analysts and highlighting uncertainty in achieving projected milestones. Our valuation report unveils the possibility XPeng's shares may be trading at a premium. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:XPEV. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
02-07-2025
- Automotive
- Yahoo
Tesla (TSLA) Shares Jump After China Sales Break 8-Month Losing Streak
July 2 - Tesla (NASDAQ:TSLA) shares jumped more than 5% on Wednesday after the company reported a 0.8% year?on?year rise in China?made electric vehicle sales for June, ending an eight?month slide. Deliveries from the Shanghai factory, including domestic sales and exports, totalled 71,599 units, up from May's pace by about 16%, data from the China Passenger Car Association showed. The recovery remains modest compared with local rivals. BYD (BYDDF) delivered a record 382,585 vehicles in June, up roughly 10% year?over?year, while NIO (NYSE:NIO) logged a 17.5% increase to 24,925 units. XPeng (NYSE:XPEV) saw the strongest growth, with sales surging 224% to 34,611 cars. In Europe, Tesla faces steeper challenges, with registrations in Denmark and Sweden plunging more than 60% last month. Investors await Tesla's Q2 delivery figures due later today, with the company's earnings report scheduled in the coming weeks. Seeking Alpha's Cavenagh Research forecasts a disappointing quarter for the Texas?based automaker. Despite competitive pressure, Tesla's slight rebound in its largest market may offer a foundation for its upcoming quarterly updates. This article first appeared on GuruFocus. Sign in to access your portfolio
